IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of Association Between Maternal Uric Acid , Maternal and Fetal Outcome in Pregnant Women With Hypertension
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by nermin marzouk agaibi, Ain Shams Maternity Hospital.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
Ain Shams Maternity Hospital
Information provided by (Responsible Party):
nermin marzouk agaibi, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier:
NCT01523327
First received: January 30, 2012
Last updated: January 31, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Association of maternal uric acid with maternal condition and fetal outcome in pregnant women with hypertension.
| Condition | Intervention |
|---|---|
| Uric Acid and Hypertension in Pregnancy | Other: measuring protein creatinin ratio,serum uric acid |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension |
Resource links provided by NLM:
Genetics Home Reference related topics:
preeclampsia
Drug Information available for:
Uric Acid
U.S. FDA Resources
Further study details as provided by nermin marzouk agaibi, Ain Shams Maternity Hospital:
| Estimated Enrollment: | 80 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | October 2012 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
A
40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
|
Other: measuring protein creatinin ratio,serum uric acid
A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate. Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method. |
|
B
40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
|
Other: measuring protein creatinin ratio,serum uric acid
A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate. Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method. |
Detailed Description:
Association of maternal uric acid with maternal condition(renal function,liver function,...ect.) and fetal outcome(birth weight,APGER score) in pregnant women with hypertension.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
The study will include 80 pregnant ladies with hypertension admitted to the maternity ward of the hospital who will be divided into two groups according to their uric acid level.
Criteria
Inclusion Criteria:
- Age:18-40 years old
- Gestational age:28-42 weeks gestation singleton pregnancy of living fetus
- Non smoker
Exclusion Criteria:
- women who refuse the study
- Any medical or obstetric disorders especially D.M.,renal disease,hepatic, cardiac disorders or gout arthritis, other than hypertension if present.
- Previously elevated uric acid level.
- Hemolytic or sickle cell anemia,urinary tract infection.
- Use of diuretics or anti-inflammatory drugs.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01523327
Please refer to this study by its ClinicalTrials.gov identifier: NCT01523327
Contacts
| Contact: Nermin marzouk touma, M.B.,B.Ch | 01222740182 ext 002 | nermindave@gmail.com | |
| Contact: nermin Marzouk touma, M.B.,B.Ch | 0862636607 ext 002 | nermindave@gmail.com |
Locations
| Egypt | |
| Ain shams maternity hospital | Recruiting |
| Cairo, Egypt, 11117 | |
| Principal Investigator: nermin marzouk touma, M.B.,B.Ch | |
Sponsors and Collaborators
Ain Shams Maternity Hospital
Investigators
| Study Director: | Mohamed Saeedeldin Elsafty, assistant lecture | Ain Shams Maternity Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | nermin marzouk agaibi, Nermin Marzouk Agaibi, Ain Shams Maternity Hospital |
| ClinicalTrials.gov Identifier: | NCT01523327 History of Changes |
| Other Study ID Numbers: |
ainshamsMH |
| Study First Received: | January 30, 2012 |
| Last Updated: | January 31, 2012 |
Keywords provided by nermin marzouk agaibi, Ain Shams Maternity Hospital:
|
Uric acid |
Additional relevant MeSH terms:
|
Hypertension Hypertension, Pregnancy-Induced Pre-Eclampsia Vascular Diseases Cardiovascular Diseases Pregnancy Complications |
Uric Acid Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 27, 2017